BIOMAT Database Logo BIOMAT Database Logo

Ondansetron treatment of L-dopa-induced psychosis. 1996

T E Eichhorn, and E Brunt, and W H Oertel

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011605 Psychoses, Substance-Induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D017294 Ondansetron A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-,Zofran ODT,GR-38032F,GR38032F,Ondansetron Hydrochloride,Ondansetron Monohydrochloride,Ondansetron Monohydrochloride Dihydrate,Ondansetron, (+,-)-Isomer,Ondansetron, (R)-Isomer,Ondansetron, (S)-Isomer,SN-307,Zofran,Dihydrate, Ondansetron Monohydrochloride,GR 38032F,Hydrochloride, Ondansetron,Monohydrochloride Dihydrate, Ondansetron,Monohydrochloride, Ondansetron,ODT, Zofran,SN 307,SN307

Related Publications

T E Eichhorn, and E Brunt, and W H Oertel
[L-dopa induced psychosis-dyskinesia complex].
March 1972, No to shinkei = Brain and nerve,
T E Eichhorn, and E Brunt, and W H Oertel
Quetiapine for l-dopa-induced psychosis in PD.
September 2000, Neurology,
T E Eichhorn, and E Brunt, and W H Oertel
Quetiapine for l-dopa-induced psychosis in PD.
April 2000, Neurology,
T E Eichhorn, and E Brunt, and W H Oertel
Response to lithium in a case of L-dopa-induced psychosis.
July 1977, The American journal of psychiatry,
T E Eichhorn, and E Brunt, and W H Oertel
L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone.
November 1995, Biological psychiatry,
T E Eichhorn, and E Brunt, and W H Oertel
[Medical treatment of L-dopa induced dyskinesia].
October 2000, Nihon rinsho. Japanese journal of clinical medicine,
T E Eichhorn, and E Brunt, and W H Oertel
[L-dopa-induced psychoses and their treatment with L-tryptophan].
April 1986, Fortschritte der Medizin,
T E Eichhorn, and E Brunt, and W H Oertel
Drug induced dystonia tarda: treatment with L-dopa.
March 1973, Diseases of the nervous system,
T E Eichhorn, and E Brunt, and W H Oertel
[L-DOPA-induced dyskinesia]
January 2002, Revue neurologique,
T E Eichhorn, and E Brunt, and W H Oertel
L-dopa-induced asterixis.
January 1985, Folia psychiatrica et neurologica japonica,
Copied contents to your clipboard!